From Behavior to Cognition: Functions of Mesostriatal, Mesolimbic, and Mesocortical Dopamine Systems

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Robbins, Trevor W ^a  

^a University of Cambridge   (United Kingdom)

Author keywords

Cognition; Mesencephalic dopamine system; Mesocortical dopamine system

Indexed keywords

EID: 84918915182     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0014     Document Type: Chapter

References (66)

1. Yerkes RM, Dodson JD. The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol. 1908;18:459-482.
2. Robbins TW, Everitt BJ. Functions of DA in the dorsal and ventral striatum. In: Robbins TW, ed. Seminars in the Neurosciences, Vol 4. London: Saunders; 1992;119-127.
3. Berridge KC. What is the role of dopamine in reward today? Psychopharmacology. 2006; 191:391-432.
4. Crow TJ. Specific monoamine systems as reward pathways. In: Wauquier A, Rolls ET, eds. Brain-Stimulation Reward. Amstredam: North-Holland; 1976;211-238.
5. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-253.
6. Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1-24.
7. Niv Y, Daw ND, Joel D, Dayan P. Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology. 2006;191:507-520.
8. Williams GV, Goldman-Rakic PS. Modulation of memory fields by DA D1 receptors in prefrontal cortex. Nature. 1995;376: 572-575.
9. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98: 6917-6922.
10. Mattay VS, Callicott JH, Fera F, et al. Catechol-O-methyltransferase val (158)-met genotype and individual variation in the response to amphetamine. Proc Natl Acad Sci USA. 2003;100: 6186-6191.
11. Durstewitz D, Seamans JK, Sejnowski T. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol. 2000;19:2807-2822.
12. Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci. 2005;8:805-812.
13. Ungerstedt U. Striatal DA release after amphetamine or nerve regeneration revealed by rotational behaviour. Acta Physiol Scand. 1971;367:49-68.
14. Carli M, Evenden JL, Robbins TW. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature. 1985;313:679-682.
15. Brown VJ, Robbins TW. Simple and choice reaction time performance following unilateral striatal DA depletion in the rat. Brain. 1991;114:513-525.
16. Lyon M, Robbins TW. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Essman W, Valzelli L, eds. Current Developments in Psychopharmacology, Vol. 2. New York: Spectrum; 1975:79-163.
17. Yin HH, Knowlton BJ, Balleine BW. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci. 2004;19:181-189.
18. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8:1481-1489.
19. Burns LH, Robbins TW, Everitt BJ. Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of d-amphetamine. Behav Brain Res. 1993;55:167-184.
20. Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 1975:94;507-522.
21. Wilkinson LS, Mittleman G, Torres E, et al. Enhancement of amphetamine-induced locomotor activity and dopamine release in nucleus accumbens following excitotoxic lesions of the hippocampus. Behav Brain Res. 1993;55:143-150.
22. Joyce EM, Iversen SD. Dissociable effects of 6-OHDA-induced lesions of neostriatum on anorexia, locomotor activity and (p.213) stereotypy-the role of behavioral competition. Psychopharmacology. 1984;83:363-366.
23. Robbins TW. Behavioural determinants of drug action; rate-dependency revisited. In: Cooper SJ, ed. Theory in Psychopharmacology, Vol. 1. London: Academic Press. 1981;1-63.
24. Robbins TW, Roberts DCS, Koob GF. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens. J Pharm Exp Ther. 1983;224:662-673.
25. Robbins TW, Taylor JR, Cador M, Everitt BJ. Limbic-striatal interactions and reward-related processes. Neurosci Biobehav Rev. 1989;13:155-162.
26. Parkinson JA, Olmstead MC, Burns LH, et al. Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive Pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by D-amphetamine. J Neurosci. 1999;19:2401-2411.
27. Everitt BJ, Parkinson JA, Olmstead MC, et al. Associative processes in addiction and reward: the role of amygdala-ventral striatal subsystems. Ann NY Acad Sci. 1999;877:412-438.
28. Wyvell CL, Berridge KC. Incentive-sensitization by previous amphetamine exposure: increased cue-triggered "wanting" for sucrose reward. J Neurosci. 2001;21:7831-784.
29. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007;315:1267-1270.
30. Cole BJ, Robbins TW. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi on peformance of a 5-choice serial reaction-time task in rats: implications for theories of selective attention and arousal. Behav Brain Res. 1989;33:165-179.
31. Pezze MA, Dalley JW, Robbins TW. Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology. 2007; 32:273-283.
32. Arnsten AFT. Catecholaminergic regulation of the prefrontal cortex. J Psychopharmacol. 1997;11:151-162.
33. Zahrt J, Taylor JR, Mathew RG, et al Supra-normal stimulation of D1 DA receptors in the rodent prefrontal cortex impairs working memory performance. J Neurosci. 1997;17:8528-8535.
34. Granon S, Passetti F, Thomas KL, et al. Enhanced and impaired attentional performance following infusion of DA receptor agents into rat prefrontal cortex. J Neurosci. 2000;20:1208-1215.
35. Chudasama Y, Robbins TW. Dopaminergic modulation, visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology. 2004;29:1628-1636.
36. Floresco SB, Phillips AG. Delay-dependent of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav Neurosci. 2001;115:934-939.
37. Phillips A, Ahn S, Floresco S. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci. 2004;14:547-553.
38. Floresco SB, Magyar O, Ghods-Sharifi S, et al. Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology. 2006;31:297-309.
39. Seamans JK, Robbins TW. Dopamine receptors and cognitive function. In: Neve K, ed. Dopamine Receptors. 2nd ed. NY: Humana Press; 2009.
40. Collins P, Roberts AC, Dias R, et al. Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and DA depletions of the prefrontal cortex. J Cogn Neurosci. 1998;10:332-354.
41. Roberts AC, De Salvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analogue of the Wisconsin Card Sorting Test: possible interactions with subcortical DA. J Neurosci. 1994;14:2531-2544.
42. Crofts HS, Dalley JW, Collins P, et al. Differential effects of 6-OHDA lesions of the prefrontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb Cortex. 2001;11:1015-1026.
43. Dias R, Robbins TW, Roberts AC. Dissociation in prefrontal cortex of affective and attentional shifts. Nature. 1996;380: 69-72.
44. Clarke HF, Walker SC, Dalley JW, et al Cognitive inflexibility after prefrontal serotonin depletion is behaviourally and neurochemically specific. Cereb Cortex. 2006;17:18-27.
45. Walker S, Clarke HF, Robbins TW, et al. Differential contributions of dopamine and serotonin to orbitofrontal cortex function in the marmoset. Cereb Cortex. 2009;19:889-898.doi:10.1093/cercor/bhn36.
46. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport. 1997;8:3581-3585.
47. Mehta MA, Swainson R, Ogilivie AD, Sahakian BJ, Robbins TW. Improved short-term memory but impaired reversal learning following the D2 agonist bromocriptine in human volunteers. Psychopharmacology. 2001;159:12-20.
48. Cools R, Sheridan M, Jacobs E, et al. Impulsive personality predicts dopamine-dependent changes in fronto-striatal activity during component processes of working memory. J Neurosci. 2007;27:5506-5514.
49. Mehta MA, Owen AM, Sahakian BJ, et al Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000;20: RC651-6.
50. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferasedeficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA. 1998;95:9991-9996.
51. Elsworth JD, Leahy DJ, Roth RH, et al. Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J Neural Transm. 1987;68:51-62
52. Karoun F, Chrpusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem. 1994;63:972-979.
53. Apud JA, Mattay V, Chen JS, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmamcology. 2007;32:1011-1020.
54. Tunbridge EM, Bannerman DM, Sharp T, et al. Catechol-Omethyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 2004;24:5331-5335.
55. Barnett JH, Jones PB, Robbins TW, et al. Effects of the catechol-Omethyltransferase Val (158)Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry. 2007;5:502-509.
56. Foltynie T, Goldberg TE, Lewis SGJ, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord. 2004;19:885-891.
57. Williams-Gray CH, Hampshire A, Robbins TW, et al. Catechol-Omethyltransferase Va1158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci. 2007;18:4832-4838.
58. Williams-Gray CH, Goris AN, Foltynie T. The two cognitive syndromes in Parkinson's disease: 5 year follow-up of a population-based incident cohort (the CamPaiGN study). Submitted for publication, 2009.
59. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain. 1988;111:299-321.
60. Swainson R, Rogers RD, Sahakian BJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of DA-ergic medication. Neuropsychologia. 1999;38:596-612.
61. Cools R, Clark L, Owen AM, et al. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci. 2002;22:4563-4567.
62. Cools R, Barker R, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11:1136-1143.
63. Collins P, Wilkinson LS, Everitt BJ, et al. The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function. Behav Neurosci. 2000;114:3-17.
64. Cools R, Lewis SJ, Clark L, et al. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology. 2007;32:180-189.
65. Cools R, Barker R, Sahakian BJ, et al. L-Dopa medication remediates cognitive inflexibility but increases impulsivity in patients with Parkinson's disease. Neuropsychologia. 2003;41:1431-1441.
66. Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron. 2009;61: 502-510.